ITRM vs. TTPH, NBRV, SPRO, SCYX, BRNS, IFRX, BNTC, CMRX, IOBT, and TLSA
Should you be buying Iterum Therapeutics stock or one of its competitors? The main competitors of Iterum Therapeutics include Tetraphase Pharmaceuticals (TTPH), Nabriva Therapeutics (NBRV), Spero Therapeutics (SPRO), SCYNEXIS (SCYX), Barinthus Biotherapeutics (BRNS), InflaRx (IFRX), Benitec Biopharma (BNTC), Chimerix (CMRX), IO Biotech (IOBT), and Tiziana Life Sciences (TLSA). These companies are all part of the "medical" sector.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) and Iterum Therapeutics (NASDAQ:ITRM) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, community ranking, dividends, media sentiment, institutional ownership, profitability, valuation and earnings.
42.3% of Tetraphase Pharmaceuticals shares are held by institutional investors. Comparatively, 9.2% of Iterum Therapeutics shares are held by institutional investors. 5.7% of Tetraphase Pharmaceuticals shares are held by insiders. Comparatively, 5.6% of Iterum Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Tetraphase Pharmaceuticals has a beta of 2.33, indicating that its stock price is 133% more volatile than the S&P 500. Comparatively, Iterum Therapeutics has a beta of 2.33, indicating that its stock price is 133% more volatile than the S&P 500.
Iterum Therapeutics has a consensus target price of $6.00, indicating a potential upside of 354.55%. Given Tetraphase Pharmaceuticals' higher probable upside, analysts clearly believe Iterum Therapeutics is more favorable than Tetraphase Pharmaceuticals.
In the previous week, Iterum Therapeutics had 2 more articles in the media than Tetraphase Pharmaceuticals. MarketBeat recorded 2 mentions for Iterum Therapeutics and 0 mentions for Tetraphase Pharmaceuticals. Tetraphase Pharmaceuticals' average media sentiment score of 1.87 beat Iterum Therapeutics' score of 0.00 indicating that Iterum Therapeutics is being referred to more favorably in the news media.
Iterum Therapeutics has lower revenue, but higher earnings than Tetraphase Pharmaceuticals. Iterum Therapeutics is trading at a lower price-to-earnings ratio than Tetraphase Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Iterum Therapeutics has a net margin of 0.00% compared to Iterum Therapeutics' net margin of -798.18%. Iterum Therapeutics' return on equity of -210.86% beat Tetraphase Pharmaceuticals' return on equity.
Tetraphase Pharmaceuticals received 247 more outperform votes than Iterum Therapeutics when rated by MarketBeat users. Likewise, 67.13% of users gave Tetraphase Pharmaceuticals an outperform vote while only 62.27% of users gave Iterum Therapeutics an outperform vote.
Summary
Iterum Therapeutics beats Tetraphase Pharmaceuticals on 8 of the 15 factors compared between the two stocks.
Get Iterum Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ITRM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ITRM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Iterum Therapeutics Competitors List
Related Companies and Tools
